Anlon Healthcare Limited released its unaudited standalone financial results for the first quarter of fiscal year 2026, covering the period ended June 30, 2025. The pharmaceutical company, which specializes in manufacturing Active Pharmaceutical Ingredients (APIs) and drug intermediates, demonstrated mixed performance with maintained profitability despite revenue challenges.

Financial Performance Overview

Anlon Healthcare reported a net profit of ₹354.69 lacs for Q1FY26, down from ₹376.35 lacs in Q1FY25. The company's revenue declined by 12% year-over-year to ₹3,329.72 lacs. Despite the revenue decrease, the company showed strong operational efficiency improvements.

The company's financial metrics for Q1FY26 showed both strengths and areas of concern when compared to the corresponding quarter of the previous year:

Revenue and Operational Analysis

Revenue from operations declined by 12.0% year-on-year to ₹3,329.72 lacs in Q1FY26 from ₹3,783.25 lacs in Q1FY25. Other income remained minimal at ₹1.17 lacs compared to ₹6.09 lacs in the previous year quarter. The company's total income decreased to ₹3,330.89 lacs from ₹3,789.34 lacs, reflecting the challenging market conditions in the pharmaceutical sector.

Cost Management and Profitability

Despite the revenue decline, Anlon Healthcare demonstrated effective cost management strategies. Total expenses decreased by 12.6% to ₹2,830.48 lacs from ₹3,236.83 lacs in Q1FY25. Key expense components showed the following changes:

• Cost of materials consumed increased to ₹2,959.48 lacs from ₹1,949.10 lacs
• Employee benefits expense rose to ₹122.49 lacs from ₹116.41 lacs
• Finance costs decreased to ₹81.71 lacs from ₹98.39 lacs
• Other expenses declined to ₹161.31 lacs from ₹201.92 lacs

Balance Sheet Strength

The company's balance sheet as of June 30, 2025, showed total assets of ₹19,775.76 lacs compared to ₹18,129.99 lacs as of March 31, 2025. Total equity increased to ₹8,396.86 lacs from ₹8,042.17 lacs, indicating strengthened shareholder value. Current assets grew significantly to ₹17,534.74 lacs from ₹15,848.09 lacs, primarily driven by increased trade receivables and inventory levels.

Cash Flow and Liquidity Position

Anlon Healthcare generated positive cash flow from operating activities of ₹117.88 lacs during the quarter. The company maintained adequate liquidity with cash and cash equivalents of ₹185.67 lacs as of June 30, 2025, compared to ₹144.96 lacs at the beginning of the period. Net cash used in financing activities was ₹74.37 lacs, while investing activities consumed ₹2.80 lacs.

Earnings Per Share Performance

Notably, the company's earnings per share showed remarkable improvement, rising to ₹2.22 in Q1FY26 from ₹0.41 in Q1FY25. This significant increase reflects the company's focus on operational efficiency and cost optimization despite the challenging revenue environment. Both basic and diluted earnings per share remained at ₹2.22 for the quarter.

Anlon Healthcare Limited has announced a strategic move to strengthen its position in the pharmaceutical intermediates market. The company has entered into a Share Purchase Agreement (SPA) to acquire a controlling stake in Apiqo Organics Private Limited, a move that aims to enhance its vertical integration and manufacturing capabilities.

Key Acquisition Details

Strategic Implications

The acquisition of Apiqo Organics is expected to bring several strategic benefits to Anlon Healthcare:

1. Vertical Integration: The move aims to enhance Anlon's vertical integration, potentially improving its supply chain efficiency and cost structure.

2. Manufacturing Capacity: The deal is set to add an additional 700-800 MT of annual manufacturing capacity for advanced pharmaceutical intermediates to Anlon's portfolio.

3. Supply Security: By acquiring Apiqo, Anlon seeks to secure a critical supply of high-quality intermediates, which could lead to more reliable production processes.

4. Market Position: The acquisition is expected to strengthen Anlon's position as a more agile, cost-competitive, and reliable partner for both innovator and generic pharmaceutical companies worldwide.

About Apiqo Organics

Apiqo Organics Private Limited, formerly known as M/s Apple Life Science, is engaged in manufacturing pharmaceutical intermediates, industrial and fine chemicals, and inorganic chemicals. The company was incorporated on December 1, 2025, following its conversion from a partnership firm to a private limited company.

Financial Snapshot of Apiqo Organics

Transaction Timeline

The acquisition is subject to customary closing conditions as outlined in the SPA. It is expected to be completed within three months from the date of signing the agreement, or as mutually agreed upon by the parties involved.

Regulatory Compliance

This disclosure has been made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The strategic acquisition by Anlon Healthcare demonstrates the company's commitment to growth and its focus on strengthening its position in the pharmaceutical intermediates market. By securing a critical supply chain component and expanding its manufacturing capabilities, Anlon aims to better serve the global pharmaceutical industry's needs.